Importer of Controlled Substances Application: Research Triangle Institute, 40160-40162 [2014-16161]
Download as PDF
<![CDATA[
tkelley on DSK3SPTVN1PROD with NOTICES
40160
Federal Register / Vol. 79, No. 133 / Friday, July 11, 2014 / Notices
Respondent and Dr. Nichol failed to
maintain dispensing records on a
current basis, see 21 U.S.C. 827(a)(3); 21
CFR 1304.21(a), Ms. Moore asserted that
she was not aware that Dr. Nichol was
required to keep controlled substances
records for the studies until August 24,
2012. Tr. 822–23. As for Respondent’s
failure to keep records, Ms. Moore
asserted that ‘‘[n]owhere in keeping
records was there ever any indication,
until [the GS] came to my site, that we
were to keep two sets of books. I never
heard that, but I’m not a registrant, so
maybe if I were, I would have heard it
and known that.’’ Id. at 565.
However, as stated above, during the
April 2011 on-site inspection, Ms.
Moore was provided with the Code of
Federal Regulations. Tr. 274. And
during the visit, one of the DIs
explained the recordkeeping
requirements to Ms. Moore. Id.
Regardless of whether Ms. Moore was
required to keep two sets of books,
Respondent was obligated to maintain
current records of the controlled
substances that were received and
dispensed by Respondent and Dr.
Nichol. Here again, Ms. Moore’s
testimony manifests that she does not
accept responsibility for the failure of
Respondent and Dr. Nichol to keep
records that complied with the CSA.
Indeed, Ms. Moore’s testimony is all the
more remarkable in light of the fact that
it occurred at a hearing at which the
issue was whether her entity should be
granted a registration. Cf. 4 OTC, Inc.,
77 FR 35031, 35035 (2012) (‘‘it is not too
much to expect that an applicant
seeking to show its intent to comply
with applicable state laws, would
produce [Standard Operating
Procedures] which were not riddled
with misstatements of those laws and
which correctly reflected those States
where its proposed method of
operations would be unlawful’’).
I therefore hold that Ms. Moore has
failed to accept responsibility for her
(and Respondent’s) misconduct. See
Jeffery P. Gunderson, 61 FR 62884,
62887 (1996). While there is no
evidence that any of the drugs that were
dispensed in the NKTR–118 study were
diverted, both the registration and
recordkeeping violations involve core
provisions of the CSA. Moreover,
Respondent’s violations of the
registration requirements were clearly
intentional. Accordingly, Ms. Moore’s
failure to acknowledge her wrongdoing
provides ample reason to reject
Respondent’s application. This
conclusion is buttressed by the ALJ’s
finding that Ms. Moore lacked candor
when she testified ‘‘concerning where
the controlled substance was actually
VerDate Mar<15>2010
20:23 Jul 10, 2014
Jkt 232001
dispensed.’’ R.D. at 34 (citing Jeri
Hassman, M.D., 75 FR 8,194, 8236
(2010), pet. for rev. denied, Hassman v.
Office of the Deputy Administrator, No.
10–70684 (9th Cir., Apr. 9, 2013)).
To be sure, Ms. Moore put on some
evidence of her willingness to comply
with the CSA and Agency regulations,
including her installation of the alarm,
her timely provision of information to
investigators, and her efforts to create
compliant records. However, where, as
here, the evidence shows that an
applicant has engaged in knowing or
intentional misconduct, Agency
precedent has long held that the
acknowledgement of such misconduct is
an essential element of rebutting the
Government’s prima facie case. See
Hoxie v. DEA, 419 F.3d at 483; see also
Medicine Shoppe, 73 FR at 387;
Kennedy, 71 FR at 35709; Daniels, 60 FR
at 62887. And in any event, the weight
to be given Ms. Moore’s evidence of her
willingness to comply is greatly
diminished by her aiding and abetting
Dr. Nichol’s violations of federal law
when he dispensed at an unregistered
location. Moreover, Ms. Moore’s
testimony shows that she still does not
understand the scope of the
recordkeeping obligations of a DEA
registrant.
Accordingly, I conclude that
Respondent’s application should be
denied.
Order
Pursuant to the authority vested in me
by 21 U.S.C. 823(f) and 28 CFR 0.100(b),
I order that the application of Moore
Clinical Trials, L.L.C., for a DEA
Certificate of Registration as a
Researcher, be, and it hereby is, denied.
This Order is effective immediately.
Dated: July 2, 2014.
Michele M. Leonhart,
Administrator.
[FR Doc. 2014–16162 Filed 7–10–14; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Importer of Controlled Substances
Application: Research Triangle
Institute
ACTION:
Notice of application.
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration in
DATES:
PO 00000
Frm 00103
Fmt 4703
Sfmt 4703
accordance with 21 CFR 1301.34(a) on
or before August 11, 2014. Such persons
may also file a written request for a
hearing on the application pursuant to
21 CFR 1301.43 on or before August 11,
2014.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/ODW, 8701
Morrissette Drive, Springfield, Virginia
22152.
SUPPLEMENTARY INFORMATION: The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, and
dispensers of controlled substances
(other than final orders in connection
with suspension, denial, or revocation
of registration) has been redelegated to
the Deputy Assistant Administrator of
the DEA Office of Diversion Control
(‘‘Deputy Assistant Administrator’’)
pursuant to sec. 7(g) of 28 CFR part 0,
subpart R, App.
In accordance with 21 CFR
1301.34(a), this is notice that on April
8, 2014, Research Triangle Institute,
Kenneth S. Rehder, Ph.D., Hermann
Building East Institute Drive, P.O. Box
12194, Research Triangle Park, North
Carolina 27709, applied to be registered
as an importer of the following basic
classes of controlled substances:
Controlled substance
AM-2201 (7201) ...........................
AM-694 (7694) .............................
JWH-018 (7118) ...........................
JWH-073 (7173) ...........................
JWH-200 (7200) ...........................
JWH-250 (6250) ...........................
JWH-019 (7019) ...........................
JWH-081 (7081) ...........................
SR-19 and RCS-4 (7104) .............
JWH-122 (7122) ...........................
JWH-203 (7203) ...........................
JWH-398 (7398) ...........................
1-(1-Phenylcyclohexyl)pyrrolidine
(7458).
1-[1-(2Thienyl)cyclohexyl]piperidine
(7470).
1-[1-(2Thienyl)cyclohexyl]pyrrolidine
(7473).
1-Methyl-4-phenyl-4propionoxypiperidine (9661).
1-(2-Phenylethyl)-4-phenyl-4acetoxypiperidine (9663).
2-(4-chloro-2,5-dimethoxyphenyl)N-(2-methoxybenzl) ethanamine
(25C-NBOMe) (7537).
E:\FR\FM\11JYN1.SGM
11JYN1
Schedule
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
40161
Federal Register / Vol. 79, No. 133 / Friday, July 11, 2014 / Notices
tkelley on DSK3SPTVN1PROD with NOTICES
Controlled substance
Schedule
2-(4-iodo-2,5-dimethoxyphenyl)-N(2-methoxybenzl) ethanamine
(25I-NBOMe) (7538).
2,5-Dimethoxy-4ethylamphetamine (7399).
2,5-Dimethoxyamphetamine
(7396).
2C-D (7508) ..................................
2C-E (7509) ..................................
2C-H (7517) ..................................
2C-N (7521) ..................................
2C-P (7524) ..................................
2C-T-2 (7385) ...............................
2C-T-7 (7348) ...............................
2C-I (7518) ...................................
2C-C (7519) ..................................
2C-T-4 (7532) ...............................
3,4,5-Trimethoxyamphetamine
(7390).
3,4-Methylenedioxyamphetamine
(7400).
3,4Methylenedioxymethamphetamine (7405).
3,4-Methylenedioxy-Nethylamphetamine (7404).
3-Fluoro-N-methylcathinone
(3FMC) (1233).
3-Methylfentanyl (9813) ................
3-Methylthiofentanyl (9833) ..........
4-Bromo-2,5dimethoxyamphetamine (7391).
4-Bromo-2,5dimethoxyphenethylamine
(7392).
4-Fluoro-N-methylcathinone
(4FMC) (1238).
4-Methyl-2,5dimethoxyamphetamine (7395).
4-Methylalphapyrrolidinopropiophenone
(4-MePPP) (7498).
4-Methylaminorex (cis isomer)
(1590).
4-Methyl-N-ethylcathinone
(4MEC) (1249).
4-Methoxyamphetamine (7411) ...
CP-47, 497 C8-homolog (7298) ...
5-Fluoro-PB-22; 5F-PB-22 (7225)
5-Methoxy-3,4methylenedioxyamphetamine
(7401).
5-Methoxy-N-Ndimethyltryptamine (7431).
5-Methoxy-N,Ndiisopropyltryptamine (7439).
AB-FUBINACA (7012) ..................
Acetorphine (9319) .......................
Acetyl-alpha-methylfentanyl
(9815).
Acetyldihydrocodeine (9051) ........
Acetylmethadol (9601) .................
ADB-PINACA (7035) ....................
Allylprodine (9602) .......................
Alphacetylmethadol except levoalphacetylmethadol (9603).
Alpha-ethyltryptamine (7249) .......
Alphameprodine (9604) ................
Alphamethadol (9605) ..................
Alpha-methylfentanyl (9814) ........
Alpha-methylthiofentanyl (9832) ...
Alpha-methyltryptamine (7432) ....
alpha-pyrrolidinopentiophenone
(a-PVP) (7545).
VerDate Mar<15>2010
20:23 Jul 10, 2014
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
Jkt 232001
Controlled substance
Schedule
alpha-pyrrolidinopentiophenone
(a-PBP) (7546).
Aminorex (1585) ...........................
APINACA and AKB48 (7048) .......
Benzethidine (9606) .....................
Benzylmorphine (9052) ................
Betacetylmethadol (9607) ............
Beta-hydroxy-3-methylfentanyl
(9831).
Beta-hydroxyfentanyl (9830) ........
Betameprodine (9608) ..................
Betamethadol (9609) ....................
Betaprodine (9611) .......................
Bufotenine (7433) .........................
Butylone (7541) ............................
CP-47, 497 (7297) ........................
Cathinone (1235) ..........................
Clonitazene (9612) .......................
Codeine methylbromide (9070) ....
Codeine-N-Oxide (9053) ..............
Cyprenorphine (9054) ..................
Desomorphine (9055) ...................
Dextromoramide (9613) ...............
Diampromide (9615) .....................
Diethylthiambutene (9616) ...........
Diethyltryptamine (7434) ..............
Difenoxin (9168) ...........................
Dihydromorphine (9145) ...............
Dimenoxadol (9617) .....................
Dimepheptanol (9618) ..................
Dimethylthiambutene (9619) ........
Dimethyltryptamine (7435) ...........
Dioxaphetyl butyrate (9621) .........
Dipipanone (9622) ........................
Drotebanol (9335) ........................
Ethylmethylthiambutene (9623) ....
Etonitazene (9624) .......................
Etorphine HCl (9056) ...................
Etoxeridine (9625) ........................
Fenethylline (1503) .......................
Furethidine (9626) ........................
Heroin (9200) ...............................
Hydromorphinol (9301) .................
Hydroxypethidine (9627) ..............
Gamma
Hydroxybutyric
Acid
(2010).
Ibogaine (7260) ............................
Ketobemidone (9628) ...................
Levomoramide (9629) ..................
Levophenacylmorphan (9631) ......
Lysergic acid diethylamide (7315)
MDPV (7535) ................................
Marihuana (7360) .........................
Mecloqualone (2572) ....................
Mephedrone (1248) ......................
Mescaline (7381) ..........................
Methaqualone (2565) ...................
Methcathinone (1237) ..................
Methyldesorphine (9302) ..............
Methyldihydromorphine (9304) .....
Methylone (7540) .........................
Morpheridine (9632) .....................
Morphine methylbromide (9305) ..
Morphine methylsulfonate (9306)
Morphine-N-Oxide (9307) .............
Myrophine (9308) .........................
N,N-Dimethylamphetamine (1480)
N-Benzylpiperazine (7493) ...........
N-Ethyl-3-piperidyl
benzilate
(7482).
N-Ethylamphetamine (1475) ........
N-Ethyl-1-phenylcyclohexylamine
(7455).
PO 00000
Frm 00104
Fmt 4703
Sfmt 4703
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
Controlled substance
N-Hydroxy-3,4methylenedioxyamphetamine
(7402).
Naphyrone (1258) ........................
Nicocodeine (9309) ......................
Nicomorphine (9312) ....................
N-Methyl-3-piperidyl
benzilate
(7484).
Noracymethadol (9633) ................
Norlevorphanol (9634) ..................
Normethadone (9635) ..................
Normorphine (9313) .....................
Norpipanone (9636) .....................
Para-Fluorofentanyl (9812) ..........
Parahexyl (7374) ..........................
Pentedrone
(amethylaminovalerophenone)
(1246).
Pentylone (7542) ..........................
Peyote (7415) ...............................
Phenadoxone (9637) ....................
Phenampromide (9638) ................
Phenomorphan (9647) .................
Phenoperidine (9641) ...................
Pholcodine (9314) ........................
Piritramide (9642) .........................
Proheptazine (9643) .....................
Properidine (9644) ........................
Propiram (9649) ...........................
Psilocybin (7437) ..........................
Psilocyn (7438) .............................
PB-22 (7222) ................................
Racemoramide (9645) ..................
SR-18 and RCS–8 (7008) ............
Tetrahydrocannabinols (7370) .....
Thebacon (9315) ..........................
Thiofentanyl (9835) ......................
Tilidine (9750) ...............................
Trimeperidine (9646) ....................
UR-144 (7144) ..............................
1-Phenylcyclohexylamine (7460)
1Piperidinocyclohexanecarbonitrile (8603).
4-Anilino-N-phenethyl-4-piperidine
(8333).
Alfentanil (9737) ...........................
Alphaprodine (9010) .....................
Amobarbital (2125) .......................
Amphetamine (1100) ....................
Anileridine (9020) .........................
Bezitramide (9800) .......................
Carfentanil (9743) .........................
Coca Leaves (9040) .....................
Cocaine (9041) .............................
Codeine (9050) .............................
Dextropropoxyphene, bulk (nondosage forms) (9273).
Dihydrocodeine (9120) .................
Dihydroetorphine (9334) ...............
Diphenoxylate (9170) ...................
Ecgonine (9180) ...........................
Ethylmorphine (9190) ...................
Etorphine HCl (9059) ...................
Fentanyl (9801) ............................
Glutethimide (2550) ......................
Hydrocodone (9193) .....................
Hydromorphone (9150) ................
Isomethadone (9226) ...................
Levo-alphacetylmethadol (9648) ..
Levomethorphan (9210) ...............
Levorphanol (9220) ......................
Lisdexamfetamine (1205) .............
Meperidine (9230) ........................
E:\FR\FM\11JYN1.SGM
11JYN1
Schedule
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
40162
Federal Register / Vol. 79, No. 133 / Friday, July 11, 2014 / Notices
Controlled substance
Schedule
tkelley on DSK3SPTVN1PROD with NOTICES
Meperidine intermediate-A (9232)
Meperidine intermediate-B (9233)
Meperidine intermediate-C (9234)
Metazocine (9240) ........................
Methadone (9250) ........................
Methadone-Intermediate (9254) ...
Methamphetamine (1105) ............
Methylphenidate (1724) ................
Metopon (9260) ............................
Moramide intermediate (9802) .....
Morphine (9300) ...........................
Nabilone (7379) ............................
Noroxymorphone (9668) ..............
Opium, raw (9600) .......................
Opium extracts (9610) ..................
Opium fluid (9620) ........................
Opium tincture (9630) ..................
Opium poppy/Poppy Straw (9650)
Oripavine (9330) ...........................
Poppy Straw Concentrate (9670)
Opium, granulated (9640) ............
Oxycodone (9143) ........................
Oxymorphone (9652) ...................
Pentobarbital (2270) .....................
Phenazocine (9715) .....................
Phencyclidine (7471) ....................
Phenmetrazine (1631) ..................
Phenylacetone (8501) ..................
Piminodine (9730) ........................
Opium, powdered (9639) .............
Racemethorphan (9732) ..............
Racemorphan (9733) ...................
Remifentanil (9739) ......................
Secobarbital (2315) ......................
Sufentanil (9740) ..........................
Tapentadol (9780) ........................
Thebaine (9333) ...........................
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
[FR Doc. 2014–16161 Filed 7–10–14; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
National Institute of Justice
[OJP (NIJ) Docket No. 1662]
National Institute of Justice
Compliance Testing Program’s
Compliant Product List for Ballistic
Body Armor
22:04 Jul 10, 2014
Jkt 232001
CTP intends to remove all older
versions of the CPLs and only maintain
the CPL associated with the current
version of the NIJ Body Armor Standard.
When NIJ Standard 0101.06 is next
revised, and for future revisions beyond
that, NIJ plans to maintain the
superseded CPL for a period of 12months after publication of the revised
standard to enable agencies to complete
purchasing actions initiated, but not
completed, when the prior version of
the standard was in effect.
Greg Ridgeway,
Acting Director, National Institute of Justice.
[FR Doc. 2014–16212 Filed 7–10–14; 8:45 am]
National Institute of Justice,
Department of Justice.
ACTION: Notice.
BILLING CODE 4410–18–P
Notice regarding the removal
of Compliant Product Lists (CPL) of
ballistic resistant body armor models
that met superseded versions of the
National Institute of Justice (NIJ) Body
Armor Standard.
DATES: Effective: August 25, 2014.
FOR FURTHER INFORMATION CONTACT:
Daniel Longhurst, NIJ CTP by email at
bactp@justnet.org, or by telephone at
(202) 616–3857.
SUPPLEMENTAL INFORMATION:
The National Institute of Justice (NIJ)supported Compliance Testing Program
(CTP) publishes on-line Compliant
Product Lists (CPLs) of ballistic resistant
body armor models that have
satisfactorily demonstrated compliance
with NIJ’s Body Armor Standard.
It has been NIJ’s practice to continue
to provide the CPLs associated with
superseded versions of the standard for
purposes of historical reference. The NIJ
CTP currently provides four CPLs
associated with the following four
specifications:
1. NIJ Standard 0101.03, Ballistic
Resistance of Police Body Armor;
2. NIJ Standard-0101.04, Ballistic
Resistance of Personal Body Armor;
3. NIJ 2005 Interim Requirements for
Bullet-Resistant Body Armor; and
4. NIJ Standard-0101.06, Ballistic
Resistance of Body Armor. (Current)
Each subsequent version of the Body
Armor standard incorporates new
research and understanding of body
armor performance with direct
implications for officer safety. The
existence of the CPLs associated with
superseded versions of the NIJ Body
Armor Standard may lead officers and
agencies to believe that the body armor
models listed on those CPLs have been
tested to the most current version of the
NIJ Body Armor Standard. To eliminate
the potential for such confusion, the
National Institute of Justice
AGENCY:
SUMMARY:
The company plans to import small
quantities of the listed controlled
substances for the National Institute on
Drug Abuse for research activities.
In reference to drug codes 7360 and
7370, the company plans to import a
synthetic cannabidiol and a synthetic
tetrahydrocannabinol. No other activity
for this drug code is authorized for this
registration.
Comments and requests for hearings
on applications to import narcotic raw
material are not appropriate. 72 FR 3417
(January 25, 2007).
In regard to the non-narcotic raw
material, any bulk manufacturer who is
presently, or is applying to be,
registered with the DEA to manufacture
such basic classes of controlled
substances listed in schedules I or II,
which fall under the authority of section
1002(a)(2)(B) of the Act (21 U.S.C.
952(a)(2)(B)) may, in the circumstances
set forth in 21 U.S.C. 958(i), file
comments or objections to the issuance
of the proposed registration and may, at
the same time, file a written request for
a hearing on such application pursuant
to 21 CFR 1301.43 and in such form as
prescribed by 21 CFR 1316.47.
VerDate Mar<15>2010
Dated: July 2, 2014.
Joseph T. Rannazzisi,
Deputy Assistant Administrator.
PO 00000
Frm 00105
Fmt 4703
Sfmt 4703
DEPARTMENT OF JUSTICE
[OJP (NIJ) Docket No. 1665]
License Plate Reader Manufacturer
Practical Assessment of Proposed
Test Methods
National Institute of Justice,
Department of Justice.
ACTION: Notice of License Plate Reader
Manufacturer Practical Assessment of
Proposed Test Methods.
AGENCY:
The National Institute of
Justice (NIJ) is inviting manufacturers of
vehicle-mounted license plate reader
(LPR) systems to participate in a
practical assessment of the proposed
test methods in the tentatively titled
Vehicle-mounted License Plate
Recognition Systems for Law
Enforcement standard under
development.
DATES: Manufacturers wishing to
participate must register with the
International Association of Chiefs of
Police no later than Friday, August 8,
2014, as instructed below. Test
evaluations will take place over two
days, Tuesday, August 19, 2014, and
Wednesday, August 20, 2014, with a
rain date of Thursday, August 21, 2014,
from 10:00 a.m. to 4:00 p.m. The test
facility will be available for
manufacturers to view the test setup and
prepare their vehicles from 9:00 to 10:00
a.m.
ADDRESSES: Location: U.S. Customs and
Border Protection Government Test
Lane Facility (GTLF) in Fredericksburg,
Virginia. Directions to the facility will
be provided upon registration.
FOR FURTHER INFORMATION CONTACT:
Manufacturers wishing to participate
must register with the International
Association of Chiefs of Police by
August 8, 2014. To register for the LPR
SUMMARY:
E:\FR\FM\11JYN1.SGM
11JYN1
]]>Agencies
[Federal Register Volume 79, Number 133 (Friday, July 11, 2014)]
[Notices]
[Pages 40160-40162]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-16161]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-392]
Importer of Controlled Substances Application: Research Triangle
Institute
ACTION: Notice of application.
-----------------------------------------------------------------------
DATES: Registered bulk manufacturers of the affected basic classes, and
applicants therefore, may file written comments on or objections to the
issuance of the proposed registration in accordance with 21 CFR
1301.34(a) on or before August 11, 2014. Such persons may also file a
written request for a hearing on the application pursuant to 21 CFR
1301.43 on or before August 11, 2014.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/ODW,
8701 Morrissette Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: The Attorney General has delegated his
authority under the Controlled Substances Act to the Administrator of
the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority
to exercise all necessary functions with respect to the promulgation
and implementation of 21 CFR part 1301, incident to the registration of
manufacturers, distributors, and dispensers of controlled substances
(other than final orders in connection with suspension, denial, or
revocation of registration) has been redelegated to the Deputy
Assistant Administrator of the DEA Office of Diversion Control
(``Deputy Assistant Administrator'') pursuant to sec. 7(g) of 28 CFR
part 0, subpart R, App.
In accordance with 21 CFR 1301.34(a), this is notice that on April
8, 2014, Research Triangle Institute, Kenneth S. Rehder, Ph.D., Hermann
Building East Institute Drive, P.O. Box 12194, Research Triangle Park,
North Carolina 27709, applied to be registered as an importer of the
following basic classes of controlled substances:
------------------------------------------------------------------------
Controlled substance Schedule
------------------------------------------------------------------------
AM-2201 (7201)............................. I
AM-694 (7694).............................. I
JWH-018 (7118)............................. I
JWH-073 (7173)............................. I
JWH-200 (7200)............................. I
JWH-250 (6250)............................. I
JWH-019 (7019)............................. I
JWH-081 (7081)............................. I
SR-19 and RCS-4 (7104)..................... I
JWH-122 (7122)............................. I
JWH-203 (7203)............................. I
JWH-398 (7398)............................. I
1-(1-Phenylcyclohexyl)pyrrolidine (7458)... I
1-[1-(2-Thienyl)cyclohexyl]piperidine I
(7470).
1-[1-(2-Thienyl)cyclohexyl]pyrrolidine I
(7473).
1-Methyl-4-phenyl-4-propionoxypiperidine I
(9661).
1-(2-Phenylethyl)-4-phenyl-4- I
acetoxypiperidine (9663).
2-(4-chloro-2,5-dimethoxyphenyl)-N-(2- I
methoxybenzl) ethanamine (25C-NBOMe)
(7537).
[[Page 40161]]
2-(4-iodo-2,5-dimethoxyphenyl)-N-(2- I
methoxybenzl) ethanamine (25I-NBOMe)
(7538).
2,5-Dimethoxy-4-ethylamphetamine (7399).... I
2,5-Dimethoxyamphetamine (7396)............ I
2C-D (7508)................................ I
2C-E (7509)................................ I
2C-H (7517)................................ I
2C-N (7521)................................ I
2C-P (7524)................................ I
2C-T-2 (7385).............................. I
2C-T-7 (7348).............................. I
2C-I (7518)................................ I
2C-C (7519)................................ I
2C-T-4 (7532).............................. I
3,4,5-Trimethoxyamphetamine (7390)......... I
3,4-Methylenedioxyamphetamine (7400)....... I
3,4-Methylenedioxymethamphetamine (7405)... I
3,4-Methylenedioxy-N-ethylamphetamine I
(7404).
3-Fluoro-N-methylcathinone (3-FMC) (1233).. I
3-Methylfentanyl (9813).................... I
3-Methylthiofentanyl (9833)................ I
4-Bromo-2,5-dimethoxyamphetamine (7391).... I
4-Bromo-2,5-dimethoxyphenethylamine (7392). I
4-Fluoro-N-methylcathinone (4-FMC) (1238).. I
4-Methyl-2,5-dimethoxyamphetamine (7395)... I
4-Methyl-alphapyrrolidinopropiophenone (4- I
MePPP) (7498).
4-Methylaminorex (cis isomer) (1590)....... I
4-Methyl-N-ethylcathinone (4-MEC) (1249)... I
4-Methoxyamphetamine (7411)................ I
CP-47, 497 C8-homolog (7298)............... I
5-Fluoro-PB-22; 5F-PB-22 (7225)............ I
5-Methoxy-3,4-methylenedioxyamphetamine I
(7401).
5-Methoxy-N-N-dimethyltryptamine (7431).... I
5-Methoxy-N,N-diisopropyltryptamine (7439). I
AB-FUBINACA (7012)......................... I
Acetorphine (9319)......................... I
Acetyl-alpha-methylfentanyl (9815)......... I
Acetyldihydrocodeine (9051)................ I
Acetylmethadol (9601)...................... I
ADB-PINACA (7035).......................... I
Allylprodine (9602)........................ I
Alphacetylmethadol except levo- I
alphacetylmethadol (9603).
Alpha-ethyltryptamine (7249)............... I
Alphameprodine (9604)...................... I
Alphamethadol (9605)....................... I
Alpha-methylfentanyl (9814)................ I
Alpha-methylthiofentanyl (9832)............ I
Alpha-methyltryptamine (7432).............. I
alpha-pyrrolidinopentiophenone ([alpha]- I
PVP) (7545).
alpha-pyrrolidinopentiophenone ([alpha]- I
PBP) (7546).
Aminorex (1585)............................ I
APINACA and AKB48 (7048)................... I
Benzethidine (9606)........................ I
Benzylmorphine (9052)...................... I
Betacetylmethadol (9607)................... I
Beta-hydroxy-3-methylfentanyl (9831)....... I
Beta-hydroxyfentanyl (9830)................ I
Betameprodine (9608)....................... I
Betamethadol (9609)........................ I
Betaprodine (9611)......................... I
Bufotenine (7433).......................... I
Butylone (7541)............................ I
CP-47, 497 (7297).......................... I
Cathinone (1235)........................... I
Clonitazene (9612)......................... I
Codeine methylbromide (9070)............... I
Codeine-N-Oxide (9053)..................... I
Cyprenorphine (9054)....................... I
Desomorphine (9055)........................ I
Dextromoramide (9613)...................... I
Diampromide (9615)......................... I
Diethylthiambutene (9616).................. I
Diethyltryptamine (7434)................... I
Difenoxin (9168)........................... I
Dihydromorphine (9145)..................... I
Dimenoxadol (9617)......................... I
Dimepheptanol (9618)....................... I
Dimethylthiambutene (9619)................. I
Dimethyltryptamine (7435).................. I
Dioxaphetyl butyrate (9621)................ I
Dipipanone (9622).......................... I
Drotebanol (9335).......................... I
Ethylmethylthiambutene (9623).............. I
Etonitazene (9624)......................... I
Etorphine HCl (9056)....................... I
Etoxeridine (9625)......................... I
Fenethylline (1503)........................ I
Furethidine (9626)......................... I
Heroin (9200).............................. I
Hydromorphinol (9301)...................... I
Hydroxypethidine (9627).................... I
Gamma Hydroxybutyric Acid (2010)........... I
Ibogaine (7260)............................ I
Ketobemidone (9628)........................ I
Levomoramide (9629)........................ I
Levophenacylmorphan (9631)................. I
Lysergic acid diethylamide (7315).......... I
MDPV (7535)................................ I
Marihuana (7360)........................... I
Mecloqualone (2572)........................ I
Mephedrone (1248).......................... I
Mescaline (7381)........................... I
Methaqualone (2565)........................ I
Methcathinone (1237)....................... I
Methyldesorphine (9302).................... I
Methyldihydromorphine (9304)............... I
Methylone (7540)........................... I
Morpheridine (9632)........................ I
Morphine methylbromide (9305).............. I
Morphine methylsulfonate (9306)............ I
Morphine-N-Oxide (9307).................... I
Myrophine (9308)........................... I
N,N-Dimethylamphetamine (1480)............. I
N-Benzylpiperazine (7493).................. I
N-Ethyl-3-piperidyl benzilate (7482)....... I
N-Ethylamphetamine (1475).................. I
N-Ethyl-1-phenylcyclohexylamine (7455)..... I
N-Hydroxy-3,4-methylenedioxyamphetamine I
(7402).
Naphyrone (1258)........................... I
Nicocodeine (9309)......................... I
Nicomorphine (9312)........................ I
N-Methyl-3-piperidyl benzilate (7484)...... I
Noracymethadol (9633)...................... I
Norlevorphanol (9634)...................... I
Normethadone (9635)........................ I
Normorphine (9313)......................... I
Norpipanone (9636)......................... I
Para-Fluorofentanyl (9812)................. I
Parahexyl (7374)........................... I
Pentedrone ([alpha]- I
methylaminovalerophenone) (1246).
Pentylone (7542)........................... I
Peyote (7415).............................. I
Phenadoxone (9637)......................... I
Phenampromide (9638)....................... I
Phenomorphan (9647)........................ I
Phenoperidine (9641)....................... I
Pholcodine (9314).......................... I
Piritramide (9642)......................... I
Proheptazine (9643)........................ I
Properidine (9644)......................... I
Propiram (9649)............................ I
Psilocybin (7437).......................... I
Psilocyn (7438)............................ I
PB-22 (7222)............................... I
Racemoramide (9645)........................ I
SR-18 and RCS-8 (7008)..................... I
Tetrahydrocannabinols (7370)............... I
Thebacon (9315)............................ I
Thiofentanyl (9835)........................ I
Tilidine (9750)............................ I
Trimeperidine (9646)....................... I
UR-144 (7144).............................. I
1-Phenylcyclohexylamine (7460)............. II
1-Piperidinocyclohexanecarbonitrile (8603). II
4-Anilino-N-phenethyl-4-piperidine (8333).. II
Alfentanil (9737).......................... II
Alphaprodine (9010)........................ II
Amobarbital (2125)......................... II
Amphetamine (1100)......................... II
Anileridine (9020)......................... II
Bezitramide (9800)......................... II
Carfentanil (9743)......................... II
Coca Leaves (9040)......................... II
Cocaine (9041)............................. II
Codeine (9050)............................. II
Dextropropoxyphene, bulk (non-dosage forms) II
(9273).
Dihydrocodeine (9120)...................... II
Dihydroetorphine (9334).................... II
Diphenoxylate (9170)....................... II
Ecgonine (9180)............................ II
Ethylmorphine (9190)....................... II
Etorphine HCl (9059)....................... II
Fentanyl (9801)............................ II
Glutethimide (2550)........................ II
Hydrocodone (9193)......................... II
Hydromorphone (9150)....................... II
Isomethadone (9226)........................ II
Levo-alphacetylmethadol (9648)............. II
Levomethorphan (9210)...................... II
Levorphanol (9220)......................... II
Lisdexamfetamine (1205).................... II
Meperidine (9230).......................... II
[[Page 40162]]
Meperidine intermediate-A (9232)........... II
Meperidine intermediate-B (9233)........... II
Meperidine intermediate-C (9234)........... II
Metazocine (9240).......................... II
Methadone (9250)........................... II
Methadone-Intermediate (9254).............. II
Methamphetamine (1105)..................... II
Methylphenidate (1724)..................... II
Metopon (9260)............................. II
Moramide intermediate (9802)............... II
Morphine (9300)............................ II
Nabilone (7379)............................ II
Noroxymorphone (9668)...................... II
Opium, raw (9600).......................... II
Opium extracts (9610)...................... II
Opium fluid (9620)......................... II
Opium tincture (9630)...................... II
Opium poppy/Poppy Straw (9650)............. II
Oripavine (9330)........................... II
Poppy Straw Concentrate (9670)............. II
Opium, granulated (9640)................... II
Oxycodone (9143)........................... II
Oxymorphone (9652)......................... II
Pentobarbital (2270)....................... II
Phenazocine (9715)......................... II
Phencyclidine (7471)....................... II
Phenmetrazine (1631)....................... II
Phenylacetone (8501)....................... II
Piminodine (9730).......................... II
Opium, powdered (9639)..................... II
Racemethorphan (9732)...................... II
Racemorphan (9733)......................... II
Remifentanil (9739)........................ II
Secobarbital (2315)........................ II
Sufentanil (9740).......................... II
Tapentadol (9780).......................... II
Thebaine (9333)............................ II
------------------------------------------------------------------------
The company plans to import small quantities of the listed
controlled substances for the National Institute on Drug Abuse for
research activities.
In reference to drug codes 7360 and 7370, the company plans to
import a synthetic cannabidiol and a synthetic tetrahydrocannabinol. No
other activity for this drug code is authorized for this registration.
Comments and requests for hearings on applications to import
narcotic raw material are not appropriate. 72 FR 3417 (January 25,
2007).
In regard to the non-narcotic raw material, any bulk manufacturer
who is presently, or is applying to be, registered with the DEA to
manufacture such basic classes of controlled substances listed in
schedules I or II, which fall under the authority of section
1002(a)(2)(B) of the Act (21 U.S.C. 952(a)(2)(B)) may, in the
circumstances set forth in 21 U.S.C. 958(i), file comments or
objections to the issuance of the proposed registration and may, at the
same time, file a written request for a hearing on such application
pursuant to 21 CFR 1301.43 and in such form as prescribed by 21 CFR
1316.47.
Dated: July 2, 2014.
Joseph T. Rannazzisi,
Deputy Assistant Administrator.
[FR Doc. 2014-16161 Filed 7-10-14; 8:45 am]
BILLING CODE 4410-09-P
